Announcements

Clinuvel's company releases, including archives.

Appendix 4E - Preliminary Final Report 2013/14

25 Aug 2014

Chairman's Update

August 18, 2014   Dear Shareholders and friends of Clinuvel, Clinuvel is approaching its first landmark regulatory decision in October and the directors of Clinuvel keenly await European Medicines Agency’s (EMA) decision on SCENESSE® (afamelanotide 16mg), our first ethical pharmaceutical product to be marketed. The expectations of the company are building and the recent unsolicited bid proposal to acquire all of Clinuvel’s outstanding shares is just one example of the heightened anticipation. The EMA is being presented with a new molecular entity which is released in the human body by a propriety and unique formulation used in a previously untreated…

Clinuvel declines unsolicited proposal from Retrophin

Non-binding offer materially undervalues Clinuvel As announced on 28 July, Clinuvel Pharmaceuticals Ltd (ASX: CUV) received an unsolicited proposal from Retrophin, Inc. (NASDAQ: RTRX) on 17 July to acquire all of the shares in Clinuvel via scheme of arrangement, for either: 0.175 Retrophin shares per Clinuvel share (valued at A$2.14 per share based on the one month VWAP of Retrophin shares on 16 July 2014); or A$2.17 in cash per Clinuvel share. The proposal was subject to numerous conditions. Retrophin has acquired a stake of approximately 6.7% in Clinuvel. The Clinuvel Board has evaluated the proposal in conjunction with its…

Appendix 3B - August 7

07 Aug 2014

Appendix 4C (Q4 2013-14)

31 Jul 2014

Appendix 3Z - Final Director's Interest Notice

31 Jul 2014

Form 603

30 Jul 2014

Proposal to acquire all the outstanding shares in Clinuvel Pharmaceuticals Ltd

28 Jul 2014

Mr Jack Wood

Clinuvel receives an unsolicited bid for the Company

Clinuvel Pharmaceuticals Limited (“Clinuvel”; ASX: CUV) received an unsolicited proposal from Retrophin, Inc. (“Retrophin” NASDAQ: RTRX)  on July 17, 2014 to acquire all of the shares in Clinuvel for either 0.175 Retrophin shares per Clinuvel share (valued at $2.14 per share based on the one month VWAP of Retrophin shares on 16 July 2014) or $2.17 in cash per share via a scheme of arrangement. The Retrophin bid values Clinuvel at approximately A$95 million2. The proposal is subject to numerous conditions. Retrophin has acquired a stake of approximately 4.88% in Clinuvel. The Board of Directors of Clinuvel is evaluating all…
Page 1 of 34

Investors' Blog Posts

In 2010, Clinuvel announced that it would commence a clinical trial of a new drug for vitiligo. In late 2012 the first treatment results...

Read More

Clinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...

Read More

Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...

Read More

Related Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Investor Spotlight